ChemoCentryx, Inc. (CCXI) Shares Bought by Wasatch Advisors Inc.

Wasatch Advisors Inc. lifted its stake in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 10.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,255,438 shares of the biopharmaceutical company’s stock after purchasing an additional 210,039 shares during the period. Wasatch Advisors Inc. owned about 4.63% of ChemoCentryx worth $21,111,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of ChemoCentryx by 1.1% during the second quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock worth $11,345,000 after purchasing an additional 13,344 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of ChemoCentryx by 3.7% during the second quarter. Acadian Asset Management LLC now owns 885,442 shares of the biopharmaceutical company’s stock worth $8,287,000 after purchasing an additional 31,724 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of ChemoCentryx by 31.0% during the first quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock worth $4,489,000 after purchasing an additional 146,000 shares during the last quarter. State Street Corp lifted its position in shares of ChemoCentryx by 7.0% during the second quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock worth $4,016,000 after purchasing an additional 27,896 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of ChemoCentryx by 9.5% during the second quarter. Northern Trust Corp now owns 276,873 shares of the biopharmaceutical company’s stock worth $2,592,000 after purchasing an additional 24,134 shares during the last quarter. 50.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of ChemoCentryx, Inc. (NASDAQ CCXI) traded up 1.02% during trading on Friday, hitting $7.89. 48,631 shares of the stock traded hands. ChemoCentryx, Inc. has a one year low of $5.19 and a one year high of $10.80. The firm has a 50 day moving average price of $7.45 and a 200-day moving average price of $7.83. The company’s market cap is $384.29 million.

ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $8.94 million for the quarter. Analysts anticipate that ChemoCentryx, Inc. will post ($0.90) earnings per share for the current fiscal year.

Several equities analysts have recently commented on CCXI shares. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Finally, BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th.

COPYRIGHT VIOLATION NOTICE: “ChemoCentryx, Inc. (CCXI) Shares Bought by Wasatch Advisors Inc.” was origin

Several other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of ChemoCentryx by 1.1% during the second quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock worth $11,345,000 after purchasing an additional 13,344 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of ChemoCentryx by 3.7% during the second quarter. Acadian Asset Management LLC now owns 885,442 shares of the biopharmaceutical company’s stock worth $8,287,000 after purchasing an additional 31,724 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of ChemoCentryx by 31.0% during the first quarter. Renaissance Technologies LLC now owns 616,581 shares of the biopharmaceutical company’s stock worth $4,489,000 after purchasing an additional 146,000 shares during the last quarter. State Street Corp lifted its position in shares of ChemoCentryx by 7.0% during the second quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock worth $4,016,000 after purchasing an additional 27,896 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of ChemoCentryx by 9.5% during the second quarter. Northern Trust Corp now owns 276,873 shares of the biopharmaceutical company’s stock worth $2,592,000 after purchasing an additional 24,134 shares during the last quarter. 50.12% of the stock is currently owned by institutional investors and hedge funds.

Shares of ChemoCentryx, Inc. (NASDAQ CCXI) traded up 1.02% during trading on Friday, hitting $7.89. 48,631 shares of the stock traded hands. ChemoCentryx, Inc. has a one year low of $5.19 and a one year high of $10.80. The firm has a 50 day moving average price of $7.45 and a 200-day moving average price of $7.83. The company’s market cap is $384.29 million.

ChemoCentryx (NASDAQ:CCXI) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). The firm had revenue of $8.94 million for the quarter. Analysts anticipate that ChemoCentryx, Inc. will post ($0.90) earnings per share for the current fiscal year.

Several equities analysts have recently commented on CCXI shares. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Finally, BidaskClub cut shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th.

COPYRIGHT VIOLATION NOTICE: “ChemoCentryx, Inc. (CCXI) Shares Bought by Wasatch Advisors Inc.” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/15/chemocentryx-inc-ccxi-shares-bought-by-wasatch-advisors-inc.html.

ChemoCentryx Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply